UK Markets closed

Verona Pharma plc (VNAPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.76000.0000 (0.00%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.7600
Open0.7600
BidN/A x N/A
AskN/A x N/A
Day's range0.7600 - 0.7600
52-week range0.5700 - 2.0000
Volume100
Avg. volume0
Market cap74.981M
Beta (5Y monthly)0.50
PE ratio (TTM)N/A
EPS (TTM)-1.6820
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021

    Results demonstrate co-administration of fluconazole has minimal effect on ensifentrine pharmacokineticsLONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces an abstract describing a drug-drug interaction study assessing the effect of CYP2C9 inhibitor, fluconazole, on the pharmacokinetics of nebulized ensifentrine in healthy individuals has been publish

  • Globe Newswire

    Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand starting at 7:00 AM EDT / 12:00 PM BST on Monday, September 13, 2021. A webcast of the

  • Globe Newswire

    Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    ENHANCE Phase 3 program on track to report top-line data in 2022 Up to $219 million strategic collaboration with Nuance Pharma in Greater China Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2021, and provides a corpora